This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dannaoui, E.
Right arrow Articles by Verweij, P. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dannaoui, E.
Right arrow Articles by Verweij, P. E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2003, p. 3647-3650, Vol. 47, No. 11
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.11.3647-3650.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Activity of Posaconazole in Treatment of Experimental Disseminated Zygomycosis

Eric Dannaoui,1* Jacques F. G. M. Meis,2 David Loebenberg,3 and Paul E. Verweij1

Department of Medical Microbiology, University Medical Center, St. Radboud, 6500 HB Nijmegen,1 Department of Medical Microbiology, Canisius-Wilhelmina Hospital, 65000 GS Nijmegen, The Netherlands,2 Schering Plough Research Institute, Kenilworth, New Jersey 070333

Received 30 June 2003/ Returned for modification 22 July 2003/ Accepted 19 August 2003

Three isolates of zygomycetes were used to produce a disseminated infection in nonimmunocompromised mice. Against all zygomycete strains, amphotericin B significantly prolonged survival. Itraconazole was inactive against Rhizopus microsporus and Rhizopus oryzae but was partially active against Absidia corymbifera. Posaconazole had no beneficial effects against R. oryzae but showed partial activity against A. corymbifera. Posaconazole had a clear dose-response effect against R. microsporus.

* Corresponding author. Present address: National Reference Center for Mycoses, Molecular Mycology Unit, Pasteur Institute, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France. Phone: 33 1 40 61 32 50. Fax: 33 1 45 68 84 20. E-mail: dannaoui{at}pasteur.fr.

Antimicrobial Agents and Chemotherapy, November 2003, p. 3647-3650, Vol. 47, No. 11
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.11.3647-3650.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Rodriguez, M. M., Pastor, F. J., Calvo, E., Salas, V., Sutton, D. A., Guarro, J. (2009). Correlation of In Vitro Activity, Serum Levels, and In Vivo Efficacy of Posaconazole against Rhizopus microsporus in a Murine Disseminated Infection. Antimicrob. Agents Chemother. 53: 5022-5025 [Abstract] [Full Text]  
  • Morris, M. I. (2009). Posaconazole: A new oral antifungal agent with an expanded spectrum of activity. Am J Health Syst Pharm 66: 225-236 [Abstract] [Full Text]  
  • Ibrahim, A. S., Gebremariam, T., Schwartz, J. A., Edwards, J. E. Jr., Spellberg, B. (2009). Posaconazole Mono- or Combination Therapy for Treatment of Murine Zygomycosis. Antimicrob. Agents Chemother. 53: 772-775 [Abstract] [Full Text]  
  • Rodriguez, M. M., Serena, C., Marine, M., Pastor, F. J., Guarro, J. (2008). Posaconazole Combined with Amphotericin B, an Effective Therapy for a Murine Disseminated Infection Caused by Rhizopus oryzae. Antimicrob. Agents Chemother. 52: 3786-3788 [Abstract] [Full Text]  
  • Perkhofer, S., Locher, M., Cuenca-Estrella, M., Ruchel, R., Wurzner, R., Dierich, M. P., Lass-Florl, C. (2008). Posaconazole Enhances the Activity of Amphotericin B against Hyphae of Zygomycetes In Vitro. Antimicrob. Agents Chemother. 52: 2636-2638 [Abstract] [Full Text]  
  • Almyroudis, N. G., Sutton, D. A., Fothergill, A. W., Rinaldi, M. G., Kusne, S. (2007). In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents. Antimicrob. Agents Chemother. 51: 2587-2590 [Abstract] [Full Text]  
  • Barchiesi, F., Spreghini, E., Santinelli, A., Fothergill, A. W., Pisa, E., Giannini, D., Rinaldi, M. G., Scalise, G. (2007). Posaconazole Prophylaxis in Experimental Systemic Zygomycosis. Antimicrob. Agents Chemother. 51: 73-77 [Abstract] [Full Text]  
  • Machouart, M., Larche, J., Burton, K., Collomb, J., Maurer, P., Cintrat, A., Biava, M. F., Greciano, S., Kuijpers, A. F. A., Contet-Audonneau, N., de Hoog, G. S., Gerard, A., Fortier, B. (2006). Genetic Identification of the Main Opportunistic Mucorales by PCR-Restriction Fragment Length Polymorphism.. J. Clin. Microbiol. 44: 805-810 [Abstract] [Full Text]  
  • Liang, K. P., Tleyjeh, I. M., Wilson, W. R., Roberts, G. D., Temesgen, Z. (2006). Rhino-Orbitocerebral Mucormycosis Caused by Apophysomyces elegans.. J. Clin. Microbiol. 44: 892-898 [Abstract] [Full Text]  
  • Schwarz, P., Bretagne, S., Gantier, J.-C., Garcia-Hermoso, D., Lortholary, O., Dromer, F., Dannaoui, E. (2006). Molecular Identification of Zygomycetes from Culture and Experimentally Infected Tissues. J. Clin. Microbiol. 44: 340-349 [Abstract] [Full Text]  
  • Antachopoulos, C., Meletiadis, J., Roilides, E., Sein, T., Walsh, T. J. (2006). Rapid Susceptibility Testing of Medically Important Zygomycetes by XTT Assay. J. Clin. Microbiol. 44: 553-560 [Abstract] [Full Text]  
  • Greenberg, R. N., Mullane, K., van Burik, J.-A. H., Raad, I., Abzug, M. J., Anstead, G., Herbrecht, R., Langston, A., Marr, K. A., Schiller, G., Schuster, M., Wingard, J. R., Gonzalez, C. E., Revankar, S. G., Corcoran, G., Kryscio, R. J., Hare, R. (2006). Posaconazole as Salvage Therapy for Zygomycosis. Antimicrob. Agents Chemother. 50: 126-133 [Abstract] [Full Text]  
  • Bialek, R, Konrad, F, Kern, J, Aepinus, C, Cecenas, L, Gonzalez, G M, Just-Nubling, G, Willinger, B, Presterl, E, Lass-Florl, C, Rickerts, V (2005). PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue. J. Clin. Pathol. 58: 1180-1184 [Abstract] [Full Text]  
  • Spellberg, B., Edwards, J. Jr., Ibrahim, A. (2005). Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management. Clin. Microbiol. Rev. 18: 556-569 [Abstract] [Full Text]  
  • Gil-Lamaignere, C., Hess, R., Salvenmoser, S., Heyn, K., Kappe, R., Muller, F.-M. C. (2005). Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes. J Antimicrob Chemother 55: 1016-1019 [Abstract] [Full Text]  
  • Carrillo-Munoz, A.-J., Quindos, G., Ruesga, M., Alonso, R., del Valle, O., Hernandez-Molina, J. M., McNicholas, P., Loebenberg, D., Santos, P. (2005). Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections. J Antimicrob Chemother 55: 317-319 [Abstract] [Full Text]  
  • Ibrahim, A. S., Bowman, J. C., Avanessian, V., Brown, K., Spellberg, B., Edwards, J. E. Jr., Douglas, C. M. (2005). Caspofungin Inhibits Rhizopus oryzae 1,3-{beta}-D-Glucan Synthase, Lowers Burden in Brain Measured by Quantitative PCR, and Improves Survival at a Low but Not a High Dose during Murine Disseminated Zygomycosis. Antimicrob. Agents Chemother. 49: 721-727 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»